Issue 6/2015
Content (17 Articles)
Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model
Maurizio Viale, Marta Rossi, Eleonora Russo, Michele Cilli, Anna Aprile, Aldo Profumo, Pierluigi Santi, Carla Fenoglio, Sergio Cafaggi, Mattia Rocco
Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
Matthew Trendowski, Timothy D. Christen, Antoaneta A. Andonova, Berlini Narampanawe, Ashlee Thibaud, Tenzin Kusang, Thomas P. Fondy
Identification of a novel compound (β-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin
Amit Kumar Tyagi, Sahdeo Prasad, Wei Yuan, Shiyou Li, Bharat B. Aggarwal
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
Jhanelle E. Gray, Jeffrey R. Infante, Les H. Brail, George R. Simon, Jennifer F. Cooksey, Suzanne F. Jones, Daphne L. Farrington, Adeline Yeo, Kimberley A. Jackson, Kay H. Chow, Maciej J. Zamek-Gliszczynski, Howard A. Burris III
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
R. van der Noll, W. M. Smit, A. N. M. Wymenga, D. S. Boss, M. Grob, A. D. R. Huitema, H. Rosing, M. M. Tibben, M. Keessen, H. Rehorst, J. H. Beijnen, J. H. M. Schellens
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J. Faivre, Anthony J. Olszanski, Karin Weigang-Köhler, Hanno Riess, Roger B. Cohen, Xuejing Wang, Scott P. Myrand, Enaksha R. Wickremsinhe, Candice L. Horn, Haojun Ouyang, Sophie Callies, Karim A. Benhadji, Eric Raymond
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort
Theresa L. Werner, Mark L. Wade, Neeraj Agarwal, Kenneth Boucher, Jesal Patel, Aaron Luebke, Sunil Sharma
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
Autumn J. McRee, Hanna K. Sanoff, Cheryl Carlson, Anastasia Ivanova, Bert H. O’Neil
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Åke Berglund, Anders Ullén, Alla Lisyanskaya, Sergey Orlov, Hans Hagberg, Bengt Tholander, Rolf Lewensohn, Peter Nygren, Jack Spira, Johan Harmenberg, Markus Jerling, Carina Alvfors, Magnus Ringbom, Eva Nordström, Karin Söderlind, Joachim Gullbo
Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
J. M. Baas, L. L. Krens, A. J. ten Tije, F. Erdkamp, T. van Wezel, H. Morreau, H. Gelderblom, H. J. Guchelaar
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
Paul L. Swiecicki, Lili Zhao, Emily Belile, Assuntina G. Sacco, Douglas B. Chepeha, Irina Dobrosotskaya, Matthew Spector, Andrew Shuman, Kelly Malloy, Jeffrey Moyer, Erin McKean, Scott McLean, Gregory T. Wolf, Avraham Eisbruch, Mark Prince, Carol Bradford, Thomas Carey, Francis P. Worden
Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Naoya Kanogawa, Tomoko Saito, Tenyu Motoyama, Akinobu Tawada, Fumihiko Kanai, Osamu Yokosuka
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients
François Ghiringhelli, Julie Vincent, Françoise Beltjens, Leila Bengrine, Sylvain Ladoire
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
Pierre Combe, Laure Chauvenet, Marie-Aude Lefrère-Belda, Hélène Blons, Caroline Rousseau, Stéphane Oudard, Eric Pujade-Lauraine
Blinatumomab for the treatment of acute lymphoblastic leukemia
Jason B. Kaplan, Marina Grischenko, Francis J. Giles
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies
Diana Markozashvili, Vincent Ribrag, Yegor S. Vassetzky
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
Geoffrey I. Shapiro, Stewart McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Daniel C. Rabe, Fabiola Cecchi, Donald P. Bottaro, Patricia LoRusso